Erlotinib HCL (Tarceva(R)) Induced Radiation Recall Dermatitis / 대한피부과학회지
Korean Journal of Dermatology
;
: 872-875, 2010.
Artículo
en Coreano
| WPRIM
| ID: wpr-63103
ABSTRACT
Erlotinib (Tarceva(R)) is a new anti-cancer agent that acts by inhibiting epidermal growth factor receptor (EGFR) signal transduction. It is currently used in the treatment of advanced stage non-small cell lung cancer and pancreatic cancer. A patient consulted our clinic and she had erythematous patches and vesicles on the submandibular area. She had taken erlotinib for the treatment of recurred lung cancer for 2 weeks. We report here on a case of radiation recall dermatitis that was induced by erlotinib in a 69-year-old woman who was previously irradiated on her submandibular area.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Neoplasias Pancreáticas
/
Quinazolinas
/
Radiodermatitis
/
Transducción de Señal
/
Carcinoma de Pulmón de Células no Pequeñas
/
Receptores ErbB
/
Clorhidrato de Erlotinib
/
Neoplasias Pulmonares
Límite:
Anciano
/
Femenino
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Dermatology
Año:
2010
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS